(S (NP (ADVP (IN In) (JJ silico)) (NP (JJ drug-target) (NN interaction) (PRN (-LRB- -LRB-) (NP (NNP DTI)) (-RRB- -RRB-)) (NN prediction))) (VP (VBZ is) (NP (NP (DT an) (ADJP (JJ important) (CC and) (VBG challenging)) (NN problem)) (PP (IN in) (NP (JJ biomedical) (NN research))) (PP (IN with) (NP (NP (DT a) (JJ huge) (JJ potential) (NN benefit)) (PP (TO to) (NP (NP (DT the) (JJ pharmaceutical) (NN industry)) (CC and) (NP (NNS patients)))))))) (. .))
(S (S (NP (NP (JJS Most) (VBG existing) (NNS methods)) (PP (IN for) (NP (NNP DTI) (NN prediction))) (PP (VBG including) (NP (JJ deep) (NN learning) (NNS models)))) (ADVP (RB generally)) (VP (VBP have) (NP (NP (JJ binary) (NNS endpoints)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB be) (NP (NP (DT an) (NN oversimplification)) (PP (IN of) (NP (DT the) (NN problem))))))))))) (, ,) (CC and) (S (NP (DT those) (NNS methods)) (VP (VBP are) (ADVP (RB typically)) (ADJP (JJ unable) (S (VP (TO to) (VP (VB handle) (NP (NP (NN cold-target) (NNS problems)) (, ,) (CONJP (INTJ (FW i.e.)) (, ,)) (NP (NP (NNS problems)) (VP (VBG involving) (NP (NP (NN target) (NN protein)) (SBAR (WHNP (WDT that)) (S (ADVP (RB never)) (VP (VBD appeared) (PP (IN in) (NP (DT the) (NN training) (NN set)))))))))))))))) (. .))
(S (PP (NNS Towards) (NP (DT this))) (, ,) (NP (PRP we)) (VP (VBD contrived) (NP (NP (NNP PADME)) (PRN (-LRB- -LRB-) (NP (NNP Protein) (CC And) (NNP Drug) (NNP Molecule) (NN interaction) (NN prEdiction)) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (NN framework)) (VP (VBN based) (PP (IN on) (NP (NNP Deep) (NNP Neural) (NNP Networks))))) (, ,) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NP (JJ real-valued) (NN interaction) (NN strength)) (PP (IN between) (NP (NNS compounds) (CC and) (NNS proteins)))) (PP (IN without) (S (VP (VBG requiring) (NP (NN feature) (NN engineering))))))))))) (. .))
(S (NP (NNP PADME)) (VP (VBZ takes) (NP (DT both) (NN compound) (CC and) (JJ protein) (NN information)) (PP (IN as) (NP (NNS inputs))) (, ,) (SBAR (IN so) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG solving) (NP (ADJP (NN cold-target) (PRN (-LRB- -LRB-) (CC and) (NN cold-drug) (-RRB- -RRB-))) (NNS problems)))))))))) (. .))
(S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (PRP we)) (VP (VBP are) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB combine) (NP (NP (NP (NNP Molecular) (NNP Graph) (NNP Convolution)) (PRN (-LRB- -LRB-) (NP (NNP MGC)) (-RRB- -RRB-))) (PP (IN for) (NP (NN compound) (NN featurization)))) (PP (IN with) (NP (JJ protein) (NNS descriptors))) (PP (IN for) (NP (NNP DTI) (NN prediction))))))))) (. .))
(S (S (NP (PRP We)) (VP (VBD used) (NP (JJ multiple) (NX (NX (NN cross-validation) (NN split) (NNS schemes)) (CC and) (NX (NN evaluation) (NNS metrics)))) (S (VP (TO to) (VP (VB measure) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (NNP PADME))) (PP (IN on) (NP (NP (JJ multiple) (NNS datasets)) (, ,) (PP (VBG including) (NP (DT the) (NNP ToxCast) (NN dataset))))))))))) (, ,) (CC and) (S (NP (NNP PADME)) (VP (ADVP (RB consistently)) (VBZ dominates) (NP (JJ baseline) (NNS methods)))) (. .))
(S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NP (DT a) (NN case) (NN study)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ predicts) (NP (NP (DT the) (VBG binding) (NN affinity)) (PP (IN between) (NP (NP (JJ various) (NNS compounds)) (CC and) (NP (NP (NN androgen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP AR)) (-RRB- -RRB-))))))))) (, ,)))) (VP (VBP suggest) (NP (NP (NP (NNP PADME) (POS 's)) (JJ potential)) (PP (IN in) (NP (NN drug) (NN development))))) (. .))
(S (NP (NP (DT The) (NN scalability)) (PP (IN of) (NP (NNP PADME)))) (VP (VBZ is) (NP (DT another) (NN advantage)) (PP (IN in) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (NNP Big) (NNP Data)))))) (. .))
